AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-03. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Jeffrey Robert Bagwell (born May 27, 1968) is an American former professional baseball player and coach. A first baseman, he spent his entire 15-year Major League Baseball (MLB) playing career with the Houston Astros. Originally a Boston Red Sox fourth-round selection from the University of Hartford in the 1989 amateur draft, Bagwell was traded to the Astros in 1990. Bagwell was named the National League (NL) Rookie of the Year in 1991 and won the NL Most Valuable Player Award (MVP) in 1994. Bagwell and longtime Astros second baseman Craig Biggio and teammate Lance Berkman were known as the "Killer B's", and the team experienced consistent success during their careers; Houston finished in first or second place in the NL Central division in eleven of twelve seasons from 1994 to 2005. During that period, the Astros qualified for the playoffs six times, culminating in Bagwell's lone World Series appearance in 2005. Bagwell hit 449 home runs for the Astros, the most in club history, and set numerous other franchise career and single-season records. He is a four-time MLB All-Star, a three-time Silver Slugger winner and a Gold Glove recipient. The only player in MLB history to have six consecutive seasons (1996–2001) with thirty home runs, 100 RBIs, 100 runs scored, and 100 walks, Bagwell is one of twelve players in history to hit 400 home runs and record an on-base percentage (OBP) of .400. He is the only first baseman with at least 400 home runs and 200 stolen bases.
During World War II, German Type XXI submarines (also known as "Elektroboote") were the first submarines designed to operate submerged for extended periods. Initially they were to carry hydrogen peroxide for long-term, fast air-independent propulsion, but were ultimately built with very large batteries instead. At the end of the War, the British and Soviets experimented with hydrogen peroxide/kerosene (paraffin) engines that could run surfaced and submerged. The results were not encouraging. Though the Soviet Union deployed a class of submarines with this engine type (codenamed Quebec by NATO), they were considered unsuccessful. The United States also used hydrogen peroxide in an experimental midget submarine, X-1. It was originally powered by a hydrogen peroxide/diesel engine and battery system until an explosion of her hydrogen peroxide supply on 20 May 1957. X-1 was later converted to use diesel–electric drive. Today several navies use air-independent propulsion. Notably Sweden uses Stirling technology on the Gotland-class and Södermanland-class submarines. The Stirling engine is heated by burning diesel fuel with liquid oxygen from cryogenic tanks. A newer development in air-independent propulsion is hydrogen fuel cells, first used on the German Type 212 submarine, with nine 34 kW or two 120 kW cells. Fuel cells are also used in the new Spanish S-80-class submarines although with the fuel stored as ethanol and then converted into hydrogen before use.
=== Hazard Course === On December 29, 2015, PSR Digital released Black Mesa: Hazard Course, a remake of Half-Life's tutorial level of the same name. The mod had been in development from 2012 to 2015 for the original mod version of Black Mesa as Crowbar Collective had not implemented a training level in the game, citing its obsolete use due to Black Mesa's use of tutorial HUD hints throughout the single-player campaign. The mod includes an intro tram ride and brief meeting with scientists reminiscent of the PlayStation 2 version of the level. In 2016, PSR Digital released an announcement that the mod had become broken due to differences between the mod version and the Steam version of Black Mesa. With fixes through the next years, the team re-released the mod for the Steam version of Black Mesa on December 29, 2020, the 5th anniversary of the mod's release.
Phenylpropanolamine (PPA; Accutrim; β-hydroxyamphetamine), also known as the stereoisomers norephedrine and norpseudoephedrine, is a psychoactive drug of the phenethylamine and amphetamine chemical classes that is used as a stimulant, decongestant, and anorectic agent. It is commonly used in prescription and over-the-counter cough and cold preparations. In veterinary medicine, it is used to control urinary incontinence in dogs under trade names Propalin and Proin. In the United States, PPA is no longer sold without a prescription due to a possible increased risk of stroke in younger women. In a few countries in Europe, however, it is still available either by prescription or sometimes over-the-counter. In Canada, it was withdrawn from the market on 31 May 2001. In India, human use of PPA and its formulations were banned on 10 February 2011.
Sources: en.wikipedia.org
== Bibliography == Biko, Steve (1979). Steve Biko: Black Consciousness in South Africa; Biko's Last Public Statement and Political Testament. Random House. ISBN 978-0-394-72739-4. Biko, Steve (2002). I Write What I Like: Selected Writings. University of Chicago Press. ISBN 978-0-226-04897-0. Clarke, Anthony J.; Fiddes, Paul S., eds. (2005). Flickering Images: Theology and Film in Dialogue. Regent's Study Guides. Vol. 12. Macon, GA: Smyth & Helwys Publishing. ISBN 1-57312-458-3. Goodwin, June (1995). Heart of Whiteness: Afrikaners Face Black Rule In the New South Africa. Scribner. ISBN 978-0-684-81365-3. Harlan, Judith (2000). Mamphela Ramphele. The Feminist Press at CUNY. ISBN 978-1-55861-226-6. Juckes, Tim (1995). Opposition in South Africa: The Leadership of Z. K. Matthews, Nelson Mandela, and Stephen Biko. Praeger Publishers. ISBN 978-0-275-94811-5. Magaziner, Daniel (2010). The Law and the Prophets: Black Consciousness in South Africa, 1968–1977. Ohio University Press. ISBN 978-0-8214-1918-2. Malan, Rian (2000). My Traitor's Heart: A South African Exile Returns to Face His Country, His Tribe, and His Conscience. Grove Press. ISBN 978-0-8021-3684-8. Omand, Roger (1989). Steve Biko and Apartheid (People & Issues). Hamish Hamilton Limited. ISBN 978-0-241-12640-0. Paul, Samuel (2009). The Ubuntu God: Deconstructing a South African Narrative of Oppression. Pickwick Publications. ISBN 978-1-55635-510-3. Pityana, Barney (1992). Bounds of Possibility: The Legacy of Steve Biko & Black Consciousness. D. Philip. ISBN 978-1-85649-047-4. Price, Linda (1992).
== History == From the time of Hippocrates it has been known that bone has considerable potential for regeneration and repair. Nicholas Senn, a surgeon at Rush Medical College in Chicago, described the utility of antiseptic decalcified bone implants in the treatment of osteomyelitis and certain bone deformities. Pierre Lacroix proposed that there might be a hypothetical substance, osteogenin, that might initiate bone growth. The biological basis of bone morphogenesis was shown by Marshall R. Urist. Urist made the key discovery that demineralized, lyophilized segments of bone induced new bone formation when implanted in muscle pouches in rabbits. This discovery was published in 1965 by Urist in Science. Urist proposed the name "Bone Morphogenetic Protein" in the scientific literature in the Journal of Dental Research in 1971. Bone induction is a sequential multistep cascade. The key steps in this cascade are chemotaxis, mitosis, and differentiation. Early studies by Hari Reddi unraveled the sequence of events involved in bone-matrix-induced bone morphogenesis. On the basis of the above work, it seemed likely that morphogens were present in the bone matrix. Using a battery of bioassays for bone formation, a systematic study was undertaken to isolate and purify putative bone morphogenetic proteins. A major stumbling block to purification was the insolubility of demineralized bone matrix. To overcome this hurdle, Hari Reddi and Kuber Sampath used dissociative extractants, such as 4M guanidine HCL, 8M urea, or 1% SDS.
Benzoic acid derivatives The benzoyl derivative cellotropin has been used for tuberculosis. Populin, which occurs in the leaves and bark of Populus tremula, is benzoyl salicin. Benzoyl-beta-D-glucoside is a compound found in the fern Pteris ensiformis.
Sources: en.wikipedia.org
[b]oth hot-iron and freeze branding cause acute pain in the first 1.5 h after branding as shown by the marked increase in cortisol. The more pronounced and prolonged elevation of cortisol observed in H animals implies that hot-iron branding may be initially (up to 40 min after branding) more distressing than freeze branding. However, there appeared to be no differences after the 40 min sampling time suggesting that the discomfort caused by both methods is relatively short lived.
=== Diabetes Mellitus === Increased levels of proinsulin in the circulatory system relative to mature insulin concentrations can indicate impending insulin resistance and the development of type 2 diabetes. Additional problems with proinsulin that can lead to diabetes include mutations in the number of cysteines present, which could affect correct folding. If the mutation causes only a mild change it could simply stress the endoplasmic reticulum’s ability to properly fold the protein. This stress, after a while, would lead to a decrease in the number of β-cells producing mature insulin, and would then lead to diabetes mellitus.
An economical semisynthesis of progesterone from the plant steroid diosgenin isolated from yams was developed by Russell Marker in 1940 for the Parke-Davis pharmaceutical company. This synthesis is known as the Marker degradation.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.